One Eleven Interactive, Inc

Innovative marketing programs for the pharmaceutical industry

One Eleven Interactive, Inc Pharmaceuticals What does the Senate really want to know about Pfizer’s deal with the US government?

What does the Senate really want to know about Pfizer’s deal with the US government?

The Senate’s top Democrat on the Homeland Security and Governmental Affairs Committee, Sen. Ron Wyden, D-Ore., said Thursday that the pharmaceutical giant had reached a settlement with the government over its treatment of some of its patients with a form of a deadly coronavirus called Pneumovirus-19.

Pfizer is a subsidiary of Johnson & Johnson, which makes the injectable drug Temazepam.

The drug, which costs $1,000 a pill, is available over-the-counter in the United States.

In a statement, the company said the deal “provides Pfizer and the Department of Health and Human Services with an additional $20 million in funding to address the pandemic and protect the public from the potential for severe adverse events.”

Wyden, a member of the Homeland Safety and Government Affairs Committee’s intelligence subcommittee, said the settlement was the largest ever for a drugmaker.

He said that Pneumavirus-17, a form that can cause severe illness, is a significant health risk to millions of Americans.

Pebola’s drug deal with US government The deal with Pfizer, a subsidiary, is the largest of its kind.

It includes $1.8 billion for research and development, including $1 billion for Pfizer to develop a new generation of Pneumivirus vaccines.

PepsiCo also agreed to buy two-thirds of the company, and to pay up to $6 billion in tax, and a $1 million fine, for its part in the Pfizer deal.

The deal with Health and Homeland Security includes $500 million in direct payments for health-care workers and other health-related activities.

In return, Health and Labor Secretary Alexander Acosta has agreed to provide $2.5 billion to Pfizer in order to reduce the costs of the Pneumvirus-18 vaccine.

The Department of Labor also has agreed in principle to provide a rebate to employers that have health care workers with Pneumravirus-1, a variant of the coronaviruses.

The deal was not disclosed Thursday, but it includes a rebate for the PPA, the trade name for the Pfizers drug.

TopBack to Top